News

In addition to the launch, the firm unveiled a new web site for Vallon LifeSciences. Doug Ruth, CEO of Vallon Holdings, said: “Our new LifeScience subsidiary will give

In the Phase II experimental infection study, treatment with ALN-RSV01 led to a decreased RSV infection rate, an increase in the number of subjects who remained free of

In addition the SFDA granted approval to Staar to market the Staar Visian ICH, an implantable collamer lens to correct hyperopia or farsightedness. These approvals in China are

The MDD submission is based on seven Phase III, placebo-controlled studies that assessed the efficacy and safety of once-daily treatment with Seroquel XR in patients diagnosed with MDD.

Under the terms of the definitive settlement agreement and in settlement and dismissal of the PDG Litigation, the company transferred to PDG the leases and associated tangible assets

In connection with the offering, the company also agreed to issue warrants to purchase an additional one million shares of its common stock with an exercise price of

Under the terms of the agreement, Crucell will be responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies.

According to Murray Aitkin, senior vice president, Healthcare Insight at IMS Health, the global pharmaceutical market is predicted to grow 5%-6% this year to a value of over

As per the paediatric regulation, which came into force in January 2007, the Commission is required to draw up guidance on the paediatric study information that must be